Bayer, Pfizer top pharma on social media, but everyone could be doing better: report

Social media Twitter Facebook Instagram Snapchat
Social media platforms still aren't key communication channels for pharma, but they should be, a new global study says. (Getty/bigtunaonline)

Pharma companies aren’t exactly blowing it on social media, but they’re also not taking full advantage of the platforms. That’s according to a new digital health check-up from Worldcom Public Relations.

The report ranked Bayer, Pfizer, Boehringer Ingelheim, Novartis and AstraZeneca, in that order, as the top pharma social channel users around the world, while Shire—now part of Takeda—and Gilead Sciences languished at the bottom of the 25 companies evaluated.

The study looked at the pharma companies’ blogs, apps, Facebook, Flickr, Instagram, LinkedIn, Pinterest, Tumblr, Twitter and YouTube. By platform, Bayer took the crown on both Facebook and Twitter, while Novartis led on LinkedIn and Pfizer ranked No. 1 on YouTube.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Want to score on social, pharma? Follow Sanofi's lead, experts say

Overall, corporate-level efforts are “fine” across the board, Serge Beckers, chairman of Worldcom’s Healthcare practice group, said. LinkedIn is well-used by most pharma companies for corporate news and sharing, while Facebook is preferred for “nice-to-know and engagement content.” Still, everyone in the category could be doing better, he pointed out—particularly on YouTube.

“One thing that was surprising is that most don’t make sufficient use of YouTube,” he said. “Video material has become much more important than it was just two years ago. … My advice would be to take some of the focus off Facebook or LinkedIn and put it on YouTube. Because as a search engine, YouTube is becoming increasingly important—it’s right up there with Google. If you want to be found as a pharmaceutical, you should be on YouTube.”

RELATED: Pharma's social media strategies are growing up—and working better, too, report finds

Another fairly simple step pharma companies can take is using local languages. Translating existing corporate messages, campaigns and posts for each country or region can make a big difference, Beckers said. It shows that pharma brands care about local markets, and besides, “if you already have the channels, which most do, why not put some effort into it and be on those channels in the local countries? It can be as simple as repurposing the content that comes from the U.S.,” he said.

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.